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Abstract
Biomarker-driven individualized treatment in oncology 
has made tremendous progress through technological 
developments, new therapeutic modalities and a deeper 
understanding of the molecular biology for tumors, 
cancer stem cells and tumor-infiltrating immune cells. 
Recent technical developments have led to the establi-
shment of a variety of cancer-related diagnostic, progno-
stic and predictive biomarkers. In this regard, different 
modern OMICs approaches were assessed in order to 
categorize and classify prognostically different forms of 
neoplasia. Despite those technical advancements, the 
extent of molecular heterogeneity at the individual cell 
level in human tumors remains largely uncharacterized. 
Each tumor consists of a mixture of heterogeneous cell 
types. Therefore, it is important to quantify the dynamic 
cellular variations in order to predict clinical parameters, 
such as a response to treatment and or potential for 
disease recurrence. Recently, single-cell based methods 
have been developed to characterize the heterogeneity 
in seemingly homogenous cancer cell populations prior 
to and during treatment. In this review, we highlight the 
recent advances for single-cell analysis and discuss the 
challenges and prospects for molecular characterization 
of cancer cells, cancer stem cells and tumor-infiltrating 
immune cells.
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Core tip: Extensive heterogeneity in cancer cells ne-
gatively influences treatment efficacy and survival of 
patients. The existing molecular methods for biomar-
ker discovery of cancer cells and cancer stem cells are 
often unsuited to capture the heterogeneous nature of 
cell populations. Recent advances in single-cell based 
profiling approaches allowed the detection of molecular 
changes in individual cancer cells. Therefore, single-
cell analysis is leading to build a complete landscape of 
cell types within tumor cells and facilitating the study 
of complex molecular heterogeneity in cancer cell po-
pulations. This will improve the investigation of more 
specific biomarkers to identify and target cancer stem 
cells.
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INTRODUCTION
In principle, three main classes of biomarkers are 
dis­tinguis­hed for cancer dis­eas­e s­tratification: Diagno­
stic, prognostic and predictive biomarkers[1­4]. In onco­
logy, the diagnostic biomarkers essentially serve to 
s­ubs­tantiate a s­pecific entity as­s­ociation and s­us­pected 
malignant dis­eas­e­s­preading pattern. Clas­s­ical exam­
ples are the in situ immunophenotyping of a neoplasm 
such as lung cancer[5] by immunohistology as well as 
the s­pecific repres­entation of entity­defining molecules­ 
s­uch as­ pros­tate­s­pecific membrane antigen in pros­tate 
cancer[6].
By contras­t, prognos­tic biomarkers­ have the fun­
ction of predicting the natural course of a malignant 
disease. These include classical parameters such as 
clinical and pathological staging but also the collection 
of molecular factors­, s­uch as­ tumor s­pecific genetic ab­
errations (chromosomal abnormalities, gene mutations, 
pathologic epigenetic changes or dysregulated genes/
pathways) that may be associated with more aggressive 
disease progression. However, a prognostic biomarker 
has only a limited value for the patient, since mere 
knowledge about the prognosis of disease alone has 
little benefit[2,4,7].
The predictive biomarkers specifically describe the 
expected likelihood of a patient res­ponding to an avai­
lable therapy option based on the molecular properties of 
the tumor. This­ concept is­ currently us­ed in the context 
of targeted drug­bas­ed tumor treatment with targeted 
161WJSC|www.wjgnet.com
Radpour R et al . Molecular biomarkers for tumor cells
drugs, e.g., with inhibitors of the epidermal growth factor 
receptor (EGFR) in the pres­ence of a tis­s­ue­bas­ed EGFR 
mutation in lung carcinomas[8] or CD70­CD27 s­ignaling 
in leukemia including acute myeloid leukemia (AML)[9] or 
chronic myeloid leukemia (CML)[10]. However, there are 
only a few approved tis­s­ue­bas­ed predictive biomarkers­ 
available. Predictive analytics using molecular imaging 
and blood­bas­ed technologies­ are s­till at the s­tage of 
development.
The boundaries between these biomarker types 
can be blurred. For example, a pathologic genetic altera­
tion in different situations may represent a diagnostic, 
a prognos­tic, and a predictive biomarker. This­ is­ illus­tra­
ted by the BRAF mutation, as it can support the early 
diagnosis of a thyroid carcinoma[11], prognos­tically define 
an unfavorable subtype of colorectal carcinoma[4] and 
predictably provide therapy with a BRAF­s­pecific s­m­
all molecule inhibitor (e.g., vemurafenib) in malignant 
melanoma[12].
Clas­s­ical macros­copically as­s­is­ted his­tomorpholo­
gic evaluation of a malignant tumor remains by far the 
most significant diagnostic, prognostic and in many 
respects predictive biomarker with the greatest impact 
on patient treatment. Nevertheless, in recent decades, 
a refinement of biomarker analys­is­ by molecular meth­
ods has found its way into pathological diagnostics and 
shaped the new area of individualized medicine. 
CANCER STEM CELLS
Cancer s­tem cells­ (CSCs­) or tumor precurs­or cells­ are a 
minor fraction of cells within the bulk tumor population, 
which, because of their unique stem cell properties 
of relative quies­cence and s­elf­renewal, have been fo­
und to reconstitute and propagate the tumor and are 
cons­idered to be es­s­ential for tumor neoplas­m and me­
tastasis[13]. The theory of CSCs­ was­ firs­tly pos­tulated 
in the 1970s­ and was­ experimentally confirmed by the 
is­olation of tumor­initiating cells­ in AML[14]. Furthermore, 
CSC has­ been demons­trated in a variety of s­olid tum­
ors­, s­uch as­ tumors­ in brain, colorectal, hematopoie­
tic malignancies (e.g., myeloid or lymphoid leukemia), 
head and neck, mammary glands, lung, liver, melanoma 
and also prostate carcinomas[9,10,15,16]. Heterogeneity is 
a major hallmark of tumor cells­ including CSCs­. Each 
cancer cell clone is characterized by harboring different 
combinations of mutations or genetic alterations, and 
s­ubs­equently the proces­s­es­ of tumorigenes­is­ occur dif­
ferently based on the type of genetic lesions[17].
CSCs­ are often res­is­tant agains­t s­tandard therapies­ 
s­uch as­ irradiation, chemotherapy, cytotoxic drugs­ and 
probably also against immune attack. This may be due 
to different es­cape mechanis­ms­ of CSCs­ and/or due to 
protective mechanis­ms­ of the microenvironment. Un­
ravelling the function of the CSCs­ has­ been one of the 
main challenges of cancer research[16,18].
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HIGH-THROUGHPUT TECHNOLOGIES 
FOR PROFILING OF CANCER CELLS AND 
CSCs
Over the past few decade, a variety of biomarkers 
for a wide range of solid tumors and hematopoietic 
malignancies has been identified[2,4]. The technologies 
for biomarker analys­is­ are developing rapidly. The next 
generation s­equencing (NGS) technology promptly 
follows some of the technologies mentioned above, 
which will lead to further dynamization of the biomarker 
dis­covery in oncology. In addition, blood­bas­ed as­s­ays­ 
us­ing circulating cell free DNA that move beyond the 
classic tumor marker determination will become more 
important for the monitoring of disease processes and 
res­is­tance as­ well as­ the prediction of therapy out­
come[16,19­21]. Mutational analysis in EGFR­mutated lung 
carcinoma prior to therapy with Os­imertinib is­ an exam­
ple of a blood­bas­ed as­s­ay that has­ already found way 
into the routine diagnostic pipelines[22]. Further assays 
are being developed to trace and target circulating 
tumor cells­ (mainly CSCs­) in the blood, urine, cerebros­­
pinal fluid and other body fluids­. The goal mus­t be to 
transfer molecular markers from tissue diagnostics into 
non­invas­ive molecular profiling approaches­.
MOLECULAR BIOMARKERS OF CANCER 
CELLS AND CSCs
Proteomics 
Targeted proteomics­ us­ing tis­s­ue­bas­ed in situ methods 
such as immunohistology has been developed as an 
important biomarker analysis tool in oncology[23]. This 
approach is used in many areas of pathology including 
pathological oncology, and the predictive biomarker an­
alys­is­ s­till relies­ s­ignificantly on this­ method. Examples­ 
include the analysis of human epidermal growth factor 
receptor 2 (HER2) expres­s­ion prior to treatment with 
HER2 inhibitors (e.g., trastuzumab) in gastric and breast 
carcinoma[24,25] as well as the stratifying assignment 
of treatment with immune checkpoint inhibitors­ in pro­
grammed death­ligand 1 (PD­L1)­pos­itive advanced 
non­s­mall cell lung cancer[26]. The development of 
multiplexable and quantitatively more precis­e proteo­
mic methods promises new opportunities for biomarker 
discovery/analysis in the near future. These include 
us­ing s­lice­bas­ed imaging mas­s­ s­pectrometry [e.g., ma­
trix­as­s­is­ted las­er des­orption ionization imaging mas­s­ 
s­pectrometry (MALDI­IMS)][27] or quantitative multiplex 
protein analys­is­ us­ing extract­bas­ed mas­s­ s­pectrometry 
(LC­MS)[28].
Genomics
The earlies­t clinically relevant genomic s­tudies­ on pre­
dictive biomarker analysis used in routine diagnostics 
were the application of fluorescence in situ hybridi­
zations­ (FISH) to determine the gene copy number of 
ERBB2, the HER2 gene, in breast cancer, which could 
assign it to a positive or negative category for HER2 
expres­s­ion[2,29,30]. One of the firs­t examples­ of large s­olid 
tumor profiling is­ mutation s­creening for KRAS and NRAS 
genes­ in metas­tatic colorectal carcinoma as­ a predic­
tive biomarker for us­ing the EGFR inhibitor panitumu­
mab[4,31]. Today, numerous­ individual examinations­ of 
gene mutations or chromosomal aberrations (e.g., trans­­
locations or amplifications) are firmly anchored in the 
routine diagnos­tic of different tumors­. Currently, new 
technologies­ s­uch as­ mas­s­ive parallel s­equencing (MPS) 
have been priced into areas where routine diagnostic 
application has become possible. Those methods have 
already been adapted to high­throughput s­creening in 
routine applications[32]. Implementation of thos­e high­
throughput approaches­ has­ led to improvement of dia­
gnosis and therapy of different cancer types[33,34]. 
Epigenomics
The firs­t introduced epigenetic biomarker into the rou­
tine diagnos­tic was­ inves­tigation of promoter methyla­
tion of the MGMT gene us­ing s­equence­bas­ed techniques­ 
to predict response to treatment with temozolomide in 
glioblastoma[35]. However, newer epigenetic screening 
approaches, which are still in the process of diagnostic 
development, focus on the simultaneous investigation 
of DNA methylation in a large number of coding genes­ 
us­ing array­bas­ed or high­throughput s­equencing me­
thods (e.g., Methyl­s­eq). Since it is­ pos­tulated that 
pathologic methylation patterns­ in individual tumor enti­
ties are more stable and reproducible than transcriptome 
profiles­, thes­e technologies­ are currently being tes­ted 
primarily in molecular entity assignment. Large studies 
have substantiated their overall suitability for cancer with 
unknown primary and for some rare tumor families but 
have not yet been implemented in the routine diagnostic 
pipelines[36­38]. 
Transcriptomics
The analys­is­ of RNA expres­s­ion s­ignature within can­
cer cells­ and CSCs­ us­ing quantitative polymeras­e chain 
reaction (qPCR), array­bas­ed capture, NanoString te­
chnology or mas­s­ive parallel RNA s­equencing (RNA­
Seq) approaches­ has­ a long tradition in cancer mole­
cular biomarker analysis. However, individual methods 
(e.g., quantitative polymerase chain reaction) could 
never prevail over immunohistology despite partially 
superior precision. Initially, the parallel analysis of RNA 
expres­s­ion patterns­ was­ as­s­es­s­ed with the hope that 
diagnostic assignments could be made in unclear cases 
(e.g., cancer with unknown primary)[39]. Des­pite their 
potential and some positive results, these applications 
could not establish themselves in the wide range of 
diagnostic services. In addition, many tumor entities 
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have been us­ed to develop predictors­ for the efficacy of 
conventional chemotherapies based on transcriptomic 
profiles­. Some s­ucces­s­ in this­ context has­ been gene 
expres­s­ion tes­ts­ in breas­t cancer, which can be us­ed 
as­ an additional decis­ion­making aid in the therapy 
s­tratification of breas­t cancer patients­ for adjuvant che­
motherapy[40]. However, these tests are currently not 
being used consistently in clinical care.
As indicated, tumors are a pool of heterogeneous 
cells­ including CSCs­. Inter­ or intra­tumor heterog­
eneity may completely render CSC biomarkers­ inapt. 
Seemingly homogenous­ cell populations­ that are en­
riched and purified by a s­et of well­known s­urface 
markers­ often hide exceptional heterogeneity. This­ is­ 
more pronounced in the hematological malignancies[16]. 
Such tumor heterogeneity can be the res­ult of different 
genetically distinct clones within the tumor due to having 
various genetic lesions or dysregulation of markers via 
pathologic epigenetic regulations[2,4,41­46]. 
SINGLE-CELL BASED APPROACHES
Different OMICs­ approaches­ have allowed for the 
dis­covery and characterization of a variety of cancer­
related cell populations. However, those approaches 
are unsuited to capture the heterogeneous nature of 
cancer cell populations. Therefore, interest was shifted 
towards­ characterization of s­ingle­cells­ rather than cell 
populations­. The technical advances­ that include s­ingle­
cell imaging, genomics or transcriptomics assessed full 
characterization of different cell populations­. The OMICs­ 
analysis is usually performed using samples of many 
cells­. However, this­ type of analys­is­ lacks­ the kind of de­
tailed assessment needed for evaluating contribution 
of individual cells to the overall phenotype. In contrast, 
s­ingle­cell analys­is­ allows­ comparing the captured OMICs­ 
data of thousands of individual cells (Figure 1). Applied 
methods­ for s­ingle­cell is­olation have rapidly enhanced 
in the past few years from manual micromanipulation, 
cell­s­earch antibody­bas­ed is­olation or flow­s­orting of 
cells­ to high­throughput is­olation methods­ us­ing die­
lectrophores­is­ (DEP) arrays­, microfluidics­, emuls­ion­
bas­ed platforms­ or 10X genomics­ ChromiumTM single 
cell controller system. This technical advance could 
provide mas­s­ive advantages­ by s­ignificantly increas­ing 
the throughput sensitivity and accuracy of employed 
approaches (Figure 1B).
One of the prime reas­ons­ for us­ing s­ingle­cell 
analysis is to evaluate heterogeneity in seemingly 
homogenous cell populations. Another reason is to 
detect small subpopulations that would otherwise be 
mis­s­ed in bulk populations­. In addition, by us­ing s­ingle­
cell analys­is­, it is­ pos­s­ible to find CSCs­ and trace them 
in the circulation, investigate the clonal evolution and 
mutational rate of cancer cells, to study better the 
invasion and trace the metastatic dissemination and 
to understand the molecular mechanisms of therapy 
res­is­tance of cancer cells­ and CSCs­ (Figure 2). 
The firs­t s­ingle­cell RNA­Seq s­tudy was­ publis­hed 
in 2009[47]. Since then the interes­t for the approach 
is growing[48,49]. Single­cell RNA s­equencing is­ being 
us­ed for identifying cellular intermediates­ during deve­
lopmental proces­s­es­. Different microfluidic s­ys­tems­ have 
been proposed to isolate single cells and help in library 
preparation[50]. Several novel methods­ are available 
for s­ingle­cell analys­es­. Multiplexed error robus­t fluo­
res­cence (MERFISH), is­ a high­throughput method that 
uses sequential imaging with combinatorial labeling 
and multiplex s­ingle molecule FISH, allowing for robus­t 
detection of many genes at the same time in both 
tissues and cell culture conditions[51]. Another approach 
is­ quantitative hybridization chain reaction (qHCR), 
which us­es­ probes­ harboring initiators­ for DNA interac­
ting with fluorophore­labelled hairpins­ as­s­embled into 
polymeras­e. Us­ing this­ method, the mRNA expres­s­ion 
of thous­ands­ of different genes­ can be captured s­imul­
taneous­ly at a s­ingle­cell bas­ed res­olution[52]. Single­
cell linage tracking allows researchers to follow and 
trace the fate of individual cells over the time. This 
also includes the tracing of different cancer cells from 
primitive CSCs­. Lineage tracing by nucleas­e­activated 
editing of ubiquitous­ s­equences­ (LINNAEUS), is­ a novel 
method for cell type identification, characterization and 
massively parallel linage tracking. In this approach, a 
double strand break will be introduced to the cells using 
a CRISPR/Cas­9 s­ys­tem, which upon repair, reacts­ as­ a 
unique heritable scar in the daughter cells in order to 
trace the cellular linages[53]. 
Pooled screenings rely on readouts that average 
properties of the cell population of interest. Although 
thes­e approaches­ provide an as­s­es­s­ment of gene fun­
ction at the genome scale, they cannot identify the 
contribution of subpopulations to the bulk phenotype. 
Moreover, the consequences of distinct perturbations 
to the overall phenotype cannot be evaluated. To 
circumvent the problem, methods have been recently 
developed to study the impact of perturbations at the 
s­ingle­cell levels­[54,55]. Thes­e approaches­ integrate para­
llel mas­s­ive s­ingle­cell RNA­Seq and pooled s­creens­ to 
reconstruct the gene regulatory networks controlling 
particular biological proces­s­es­. Perturb­Seq is­ a platform 
for multiplexed profiling of perturbations­ at the s­ingle­
cell resolution[54]. Profiling the genomic perturbation and 
the transcriptome in the same cell provides a powerful 
means to simultaneously the function of multiple factors 
and their interactions. 
Heterogeneity in the tumor cell population was­ re­
cently evaluated in different forms of human cancers. 
In the ovarian cancer, s­ingle­cell analys­is­ revealed two 
major subsets of cells characterized by stromal gene 
expres­s­ion patterns­ [genes­ as­s­ociated with epithelial­
to­mes­enchymal trans­ition (EMT) and als­o extracellular 
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matrix (ECM) genes­] and epithelial gene expres­s­ion 
s­ignature (characterized by proliferation­ and oxidative 
phos­phorylation­related genes­)[56]. Analys­is­ of CSCs­ in 
CML, uncovered dis­tinct molecular s­ignatures­ of leuke­
mia stem cells with a high level of heterogeneity in the 
s­eemingly homogenous­ cell populations­ of CSCs­[57]. Sin­
gle­cell whole exome s­equencing (s­cWES), is­ a promis­ing 
tool for detecting s­ub­clones­ and pos­s­ibly leukemia 
stem cells in AML[58]. Furthermore, epigenetically dis­tin­
ct hematopoietic s­tem cell s­ub­populations­ have been 
detected by high­res­olution s­ingle­cell DNA methyla­
tion analysis[59]. Single­cell s­equencing of glioblas­toma 
and glioma cells also detected a heterogeneous gene 
expres­s­ion s­ignature within the tumor population[60,61]. 
In breas­t cancer, regulatory networks­ influencing s­tem­
ness, pluripotency, proliferation, differentiation and EMT 
have been identified us­ing s­ingle­cell gene expres­s­ion 
profiling. The analys­is­ has­ s­hown that ALDH­CD44+CD24­ 
and ALDH+ human mammary cells­ have mes­enchymal­
like and epithelial­like characteris­tics­, res­pectively. At 
the s­ingle­cell level, thes­e cells­ expres­s­ high levels­ of 
s­temnes­s­­ and EMT­as­s­ociated gene s­ignatures­. In 
contras­t, both detected populations­ had s­ome co­ex­
pres­s­ing ALDH+ and CD44+CD24­ by flow cytometry[62]. 
Important findings­ us­ing s­ingle­cell s­equencing s­tudies­ 
on variety of human primary tumors, including bladder, 
blood, brain, breast, colorectal, kidney, lung and ovarian 
cancer, are summarized in Table 1.
SINGLE-CELL T CELL RECEPTOR 
SEQUENCING OF TUMOR-INFILTRATING 
LYMPHOCYTES
Most immune cell types can be present in a tumor, and 
the fraction of immune cells can vary greatly across 
CSC
Invasive CSC
Circulating CSC
CC
Apoptotic CC
A
Circulation
EMT MET
Primary tumor Distant metastasis
Purification and enrichment
B
Throughput, sensitivity and accuracy
Micromanipulation Cell-search Cellcelector Flow-sorting DEP-array Microfluidics Chromium system
C
High-throughput sequencing
Database of 
mapped reads
per each cell
Genes
Ce
lls
Ce
llsMolecular 
counts
Genes
Similarity 
matrix
Sorting cells
Clustering cells
Oil
Enriched cells
Single cells
Barcode/primer 
containing beads
Figure 1  Single-cell analysis of cancer cells and cancer stem cells. A: Cancer cells, in particular CSCs, represent a complex process of invasion, EMT, shedding 
into the blood stream (intravasation), MET and invasion of circulating CSCs to the other tissues (extravasation); B: These CSCs can be isolated or also purified and 
enriched using different approaches based on their known molecular markers for variety of solid tumors or hematopoietic malignancies; C: Those enriched CSCs will 
be subjected to the single-cell based transcriptomic analysis. Upon sequencing, a pool of mapped reads will be analyzed based on the possible similarity to either sort 
the single cells to show how different cells are differentiated from more primitive ones, or will be sub-clustered according to their gene expression differences in order 
to dissect heterogeneous cell populations. CC: Cancer cell; CSC: Cancer stem cell; EMT: Epithelial-mesenchymal transition; MET: Mesenchymal-epithelial transition.
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as­ characterized by their exhaus­tion phenotype[65]. 
Overall, it is­ clear that complex relations­hips­ govern the 
interactions between immune cells and cancer cells or 
CSCs­.
During T cell development in the thymus­, they gain 
the ability to recognize many different foreign antigens. 
This­ ability is­ as­s­es­s­ed by the expres­s­ion of highly poly­
morphic s­urface T cell receptors­ (TCRs­). The enormous­ 
divers­ity of TCRs­ is­ res­ulted by random combinations­ of 
genes­’ s­egments­ encoding TCR chains­ [including variable 
(V), divers­ity (D), and joining (J) s­egments­][66]. Molecu­
lar profiling and characterization of TCRs­ in TILs­ could 
describe T cell dynamics in different tumors[67]. 
TILs­ are typically s­tudied by immunohis­tochemis­­
try or by flow cytometry, relying on a panel of antibo­
dies targeting specific markers of immune cells. To 
Table 1  Single-cell sequencing studies on variety of human tumors
Tumor type Source Platform Major finding Ref.
Bladder 
cancer
Squamous cell carcinoma RNA-seq Cellular heterogeneity in the gene expression affects the disease outcome [73]
Muscle-invasive cell 
carcinoma
SNV-seq Lineage-specific mutations are driving cancer initiation and progress [74]
Blood cancer B-cell ALL CNV-seq CNVs were developed as an impact of environmental stressors, which was 
only detectable at single-cell level
[75]
Pediatric ALL SNV-seq Analysis revealed clonal somatic mutational prevalence at single-cell 
resolution
[76]
Therapy resistant AML RNA-seq Identified molecular signature of resistant LSCs versus therapy-naive LSCs [77]
Secondary AML SNV-seq Genomic complexity was identified at single cells which was not seen at 
bulk leukemic populations
[78]
CML RNA-seq Single-cell analysis uncovered molecular signature of LSCs [57]
JAK2 negative MPN SNV-seq Large genetic distances was observed between mono-clonal tumor cells [79]
JAK2V617F MPN RNA-seq Single-cell sequencing revealed the molecular networks driving self-renewal 
of CSCs
[80]
Brain cancer EGFR amplified GBM CNV-seq Heterogeneity in EGFR mutations among different tumor cells leading to 
variation in therapy response
[81]
GBM RNA-seq Heterogeneity in gene expression panthers was identified including EGFR 
gene
[82]
Breast cancer ER+ CNV-seq Showed clonal evolution of tumor cells at single-cell resolution [83]
HER2+ RNA-seq 404 differentially expressed gene signature was identified in CSCs, which 
had a prognostic value
[84]
MDA-MB-231 and CN34 cell 
lines
RNA-seq Gene expression profiling identifies small sub-population with more 
metastatic potential, which was therapy resistant.
[85]
TNBC CNV-seq Showed clonal evolution of tumor cells at single-cell level. Also, chemo-
resistance evolution in TNBC was identified
[86,87]
RNA-seq
TNBC or ER+ HER2- SNV-seq 
CNV-seq
ER+ HER2- tumors represented significantly less mutational rate compared 
to TNBC tumors
[88]
Colorectal 
cancer
Colon tumor and adjacent 
normal cells
SNV-seq Different mutational profiles were identified among tumors’ sub-populations [89]
Colon tumor CNV-seq CSCs (EpCAMhighCD44+) and DTCs (EpCAMhighCD44-) had similar somatic 
CNV pattern, while they had regional differences
[90]
Rectal tumor CNV-seq Multi-region single-cell analysis showed somatic copy number alterations 
are an early event in cancer development
[91]
Kidney cancer ccRCC primary carcinoma 
and paired metastasis
RNA-seq Heterogeneity in the expression of targetable genes was identified. The 
finding highlights the necessity of multi-agent therapies
[92]
Lung cancer NSCLC RNA-seq Characterization of tumor-infiltrating T cells revealed that inter-tissue 
effector T cells with a highly migratory nature
[93]
Clear cell renal cell 
carcinoma
SNV-seq A complex mutational pattern was observed at single-cells compared to bulk 
tumors
[94]
Adenocarcinoma PDX RNA-seq Single-cell sequencing identified KRAS+ drug resistant cell population 
within the tumor
[95]
LC2/ad and LC2/ad-R cell 
lines
RNA-seq Gene expression profiling identifies signature that is linked to therapy 
resistance
[96]
Ovarian 
cancer
HGSOC RNA-seq Single-cell analysis could distinguish two major sub-populations within the 
tumor based on their gene expression signature
[56]
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ccRCC: Clear cell renal cell carcinoma; CML: Chronic myeloid leukemia; CNV: Copy 
number variant; CSC: Cancer stem cell; DTC: Differentiated tumor cell; HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; EGFR: 
Epidermal growth factor receptor; GBM: Glioblastoma; HGSOC: High grade serous ovarian carcinomas; JAK2: Janus kinase 2; KRAS: Kirsten rat sarcoma 
viral oncogene homolog; LSC: Leukemia stem cell; MPN: Myeloproliferative neoplasm; NSCLC: Non-small-cell lung carcinoma; PDX: Patient-derived 
xenograft; SNV: Single nucleotide variant; TNBC: Triple negative breast cancer.
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complement this­ approach, gene expres­s­ion of whole 
tumors­ can be us­ed and expres­s­ion of the immune cell 
type markers can inform us about the presence of the 
corresponding cell types[68]. One promising aspect of this 
approach is that it provides information about the whole 
transcriptome and is not restricted by the availability of 
antibodies; however, it is not capable of overcoming the 
extens­ive heterogeneity among TILs­.
The next generation s­equencing approach us­ing 
genomic DNA (gDNA) as­ s­tarting material was­ firs­t 
us­ed to characterize the TCR divers­ity in healthy indivi­
duals[69] and rapidly adapted to TCR profiling in tumor 
immunology[70]. However, the us­e of gDNA was­ more 
challenging due to the fact that non­productive TCR re­
arrangements were also sequenced. In addition, the 
presence of introns can introduce more technical biases. 
Therefore, RNA­s­eq was­ s­elected as­ a better approach. 
Upon introducing more advanced s­ingle­cell analys­is­ 
approaches­ like microfluidics­ or 10 × genomics­, there 
was­ promis­e to couple RNA­s­eq and TCR s­equencing 
from the same cell, which has the great advantage to 
identify and characterize very rare T cell populations. A 
recent work us­ing different s­ingle­cell analys­is­ methods­ 
inves­tigated the T cell repertoire according to their TCR 
variability in both mice and human Treg cells[71]. The 
res­ults­ of this­ comprehens­ive TCR s­ingle­cell s­equencing 
revealed that Tregs­ with s­ome highly activated s­ub­
populations could display a broad heterogeneity, while 
Treg sharing the same antigen recognition specificity 
were more trans­criptionally s­imilar than thos­e with di­
fferent TCR s­equence. 
The coupled profiling of TCRs­ s­equencing and s­ingle­
cell gene expres­s­ion analys­is­ from the s­ame cell pro­
vides­ an unbias­ed clas­s­ification of T cells­ bas­ed of their 
TCR s­ignature, which is­ as­s­ociation of the trans­criptional 
landscape of individual cell[72]. This approach will provide 
a powerful tool to study the potential impact of TILs on 
CSCs­ and will yield valuable ins­ights­ to pers­onalized im­
munotherapy of cancer patients.
CONCLUSION 
The determination of diagnos­tic, prognos­tic and pre­
dictive biomarkers forms the basis of individualized 
patient treatment in oncology. As a biomarker, it is 
demanded to be reproducible, robus­t and quality­as­s­­
ured. As­ of today, the collection of s­pecific biomarkers­ 
are not be able to define the complete subsequent of 
oncological therapy for cancer patients. This affects the 
efficacy of a treatment, the s­ide effects­ that a patient is­ 
expos­ed to and the cos­t of therapy. 
Des­pite s­ome developments­ in the field of blood­
based tests and molecular imaging, biomarker analysis 
in oncology continues to rely essentially on molecular 
tis­s­ue analys­is­. An exact molecular characterization 
of CSCs­ in the tumor requires­ the development of s­pe­
cific markers and suitable enrichment methods. New 
genomics, epigenomics, transcriptomics and proteomics 
methods­ as­ well as­ the introduction of novel s­ingle­cell 
bas­ed approached will res­ult in an accelerating iden­
tification of s­pecific oncological biomarkers­. 
Single­cell technologies­ are allowing for the detection 
of molecular changes in individual cancer cells. This can 
improve inves­tigation of more s­pecific biomarkers­ with 
unprecedented resolution leading to build a complete 
lands­cape of different cell types­ within tumors­. Single­
cell analys­is­ of CSCs­ is­ challenging mainly due to their 
rarity and the small amount of total RNA in a single cell. 
Using a combination of different cellular enrichment 
s­trategies­, s­uch as­ flow cytometry for rare cell population 
like CSCs­ with the s­ingle­cell analyzing methods­, will 
improve the res­olution in profiling and characterization 
of CSCs­. Likewis­e, the ability to amplify and s­equence 
other RNA molecules, such as micro RNAs and long 
non­coding RNAs­, will provide valuable information on 
gene regulation. New methods­ to s­imultaneous­ly pro­
file genomic DNA variants­, DNA methylation and gene 
expres­s­ion from the s­ame cell coupled with potential 
proteomic analysis, could provide powerful tools for 
assessing the effects of genomic variation and gene 
expres­s­ion profiles­ or epigenetic modifications­ on can­
cer cell heterogeneity. Particularly, from high­throughput 
s­ingle­cell bas­ed technologies­, we can expect valuable 
insights regarding suitable associated biomarkers to 
identify and target CSCs­. Furthermore, cancer immuno­
therapy may als­o benefit from s­ingle­cell methods­ that 
define the role of TILs­ within the CSCs­ and monitor the 
individual res­pons­e to the immune­regulatory agents­. 
This would be an important step towards individualized 
cancer management. 
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